Whitepaper: CMC regulatory landscape, cell and gene therapy products
This whitepaper gives an understanding of the evolving regulatory guidelines for cell and gene therapies, in order to bring them to market faster.
Like all biotech products, getting life-saving medicines to market quickly can be delayed if you’re not prepared for regulatory inspections. Whether you’re a large or new and emerging biotech company, many companies find themselves lacking the internal resources and/or expertise to properly support regulatory filings.
Learn more about:
- Unique attributes of viral vector products
- Clinical and regulatory landscape for cell and gene therapies
- Regulatory and CMC challenges.
Related content from this organisation
- Technical note: System precision in HPLC analysis of APIs and impurities
- Event review: The Future of QA/QC for Complex Biologics
- Application note: Achieve complete lab access with extended reality LIMS software
- Application Notes Supplement 2021
- Many hands make light work: why the new Bespoke Gene Therapy Consortium is a godsend for ambitious biopharma teams
Biologics, Biopharmaceuticals, Drug Delivery Systems, Excipients, Formulation, Freeze Drying, Gene therapy, Good Manufacturing Practice (GMP), Ingredients, Manufacturing, Microbiology, Outsourcing, Packaging, QA/QC, Regulation & Legislation, Research & Development (R&D), Stem Cells, Supply Chain, Vaccines